Ann: First Key Appointments to Medical Advisory Board, page-2

Nice appointments. Once again validation that IHL and Cannvalate aren't mucking around with these trials and that they are the real deal. These gents would not sign on if they thoughts these weren't relevant trials with potential huge upside. The market will eventually see just how well this company is being built out. Don't forget we keep all the IP around the trials. So much value adding to the share price in front of us over the next few months.